A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
Mirror Now on MSN
Dr Reddy’s partners with Gilead to expand access to once-yearly HIV prevention drug
Hyderabad-based Dr Reddy’s Laboratories has signed a royalty-free licensing agreement with Gilead Sciences to manufacture and ...
Gilead Sciences (GILD) has expanded the scope of its six royalty-free lenacapavir voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevent ...
Low perceived HIV risk despite reported high-risk behaviors suggests major educational gaps in correctional settings and ...
HIV drug lenacapavir, a twice yearly injectable pre-exposure prophylaxis (PrEP), has been rejected by the National Institute ...
Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...
LUSAKA-(MaraviPost)-Zambia has taken delivery of its first US-government funded consignment of lenacapavir, a new HIV prevention drug that requires just two injections a year. Health officials say the ...
Pre-exposure prophylaxis (PrEP) has emerged as a cornerstone of HIV prevention, employing antiretroviral agents in HIV-negative individuals at substantial risk of infection. Strategies to optimise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results